Alembic Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 04 Feb 2025
Result Summary
- Alembic Pharmaceuticals Ltd reported a 2.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.2%.
- Its expenses for the quarter were up by 1.8% QoQ and 5.2% YoY.
- The net profit decreased 10.1% QoQ and decreased 23.7% YoY.
- The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1702.24 | 1664.72 | 1633.46 | 2.3% | 4.2% |
Total Expenses | 1524.82 | 1498.03 | 1448.83 | 1.8% | 5.2% |
Profit Before Tax | 177.42 | 179.56 | 184.63 | -1.2% | -3.9% |
Tax | 40.08 | 27.28 | 4.13 | 46.9% | 870.5% |
Profit After Tax | 137.70 | 153.14 | 180.45 | -10.1% | -23.7% |
Earnings Per Share | 7.00 | 7.80 | 9.20 | -10.3% | -23.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alembic Pharmaceuticals Ltd is a leading Indian pharmaceutical company known for its focus on manufacturing and marketing high-quality generic drugs. As part of the pharmaceutical industry, Alembic is engaged in the research, development, and production of active pharmaceutical ingredients (APIs) and formulations. The company has a substantial presence in both domestic and international markets, providing a diverse range of products including generic formulations, branded generics, and specialty medicines. Alembic Pharmaceuticals is committed to innovation and quality, leveraging its research and development capabilities to expand its product portfolio. While specific recent developments are not detailed here, the company is known for strategic expansions and investments in new markets and product lines.
Revenue
In Q3FY25, Alembic Pharmaceuticals reported a total income of ₹1702.24 crores, reflecting a quarter-over-quarter (QoQ) increase of 2.3% from ₹1664.72 crores in Q2FY25. Year-over-year (YoY), there was a 4.2% increase compared to the total income of ₹1633.46 crores in Q3FY24. The steady growth in total income highlights the company's ability to generate revenue consistently over the quarters. The QoQ and YoY growth in total income suggests a positive trend in the company's revenue generation capabilities, maintaining a trajectory of growth over the analyzed periods.
Profitability
The profit before tax for Q3FY25 was ₹177.42 crores, a slight decrease of 1.2% from ₹179.56 crores in Q2FY25. Compared to Q3FY24, where the profit before tax was ₹184.63 crores, there was a YoY decline of 3.9%. Tax expenses in Q3FY25 were ₹40.08 crores, witnessing a significant QoQ increase of 46.9% from ₹27.28 crores in Q2FY25 and a dramatic YoY rise of 870.5% from ₹4.13 crores in Q3FY24. Consequently, the profit after tax for Q3FY25 stood at ₹137.70 crores, down by 10.1% QoQ from ₹153.14 crores in Q2FY25 and 23.7% YoY from ₹180.45 crores in Q3FY24. Earnings per share (EPS) in Q3FY25 were ₹7.00, showing a decline of 10.3% from Q2FY25 and 23.9% from Q3FY24. These figures highlight changes in profitability metrics over the periods analyzed.
Operating Metrics
Alembic Pharmaceuticals' total expenses for Q3FY25 were ₹1524.82 crores, marking a 1.8% increase QoQ from ₹1498.03 crores in Q2FY25, and a 5.2% increase YoY from ₹1448.83 crores in Q3FY24. The increase in total expenses corresponds with the overall revenue growth, indicating cost management in line with income generation. While profit before tax showed a decrease, the increased tax expenses significantly impacted the net profit figures. The changes in operating metrics are evident when observing the trends in both income and expenses over the quarters, providing insights into the company's operational efficiency and financial management within the given periods.
